sarepta shares tumble as concerns mount over fda approval on gene therapy
Published 1 year ago • 1.3K plays • Length 2:47Download video MP4
Download video MP3
Similar videos
-
3:51
td cowen's ritu bara talks sarepta stock skyrocketing on fda gene therapy approval
-
5:43
sarepta ceo on what's next after expanded muscular dystrophy drug approval
-
6:41
former fda commissioner dr. scott gottlieb on the future of gene therapy
-
3:43
fda board votes to approve gene therapy for duchenne muscular dystrophy
-
3:18
sarepta therapeutics ceo on soaring stock and drug development
-
4:05
red & green flags of: retail investing
-
10:06
20% to 30% pullback will counter "sugar high" market
-
19:43
long term stock charts
-
4:09
watch cnbc's full interview with sarepta ceo doug ingram
-
2:18
gene therapy assessments in clinical trials (spanish subtitles)
-
0:39
sarepta working on groundbreaking gene therapies in central ohio
-
0:19
sarepta surges after fda panel backs duchenne gene therapy|#shorts
-
2:50
gt-faq: how long is gene therapy expected to last?
-
1:44
sarepta soars on expanded approval for muscular dystrophy drug
-
2:45
gt-faq: how is safety measured in a gene therapy clinical trial?
-
2:41
gt-faq: is gene therapy specific to a mutation?
-
2:43
is gene therapy right for me?
-
0:51
keeping patients at the forefront of everything we do
-
0:22
us fda advisers narrowly back sarepta's duchenne gene therapy for accelerated approval|#shorts
-
20:57
overview of preexisting antibody testing prior to aav gene therapy presented by sarepta therapeutics
-
2:31
gt-faq: what are eligibility criteria for gene therapy clinical trials?
-
2:42
what are pre-existing antibodies, and why do they matter to gene therapy?